Abstract | OBJECTIVES: BACKGROUND: METHODS: RESULTS: Oral ximelagatran, intravenous r- hirudin and subcutaneous enoxaparin rapidly and significantly (p < 0.05) decreased F1+2, TAT and beta-TG levels in shed blood, indicating inhibition of thrombin generation and platelet activation. Statistically significant concentration ( melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected. Melagatran showed dose-proportional pharmacokinetics with low variability. All drugs were well tolerated. CONCLUSIONS:
|
Authors | Troy C Sarich, Michael Wolzt, Ulf G Eriksson, Christer Mattsson, Alice Schmidt, Susanne Elg, Magnus Andersson, Maria Wollbratt, Gunnar Fager, David Gustafsson |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 41
Issue 4
Pg. 557-64
(Feb 19 2003)
ISSN: 0735-1097 [Print] United States |
PMID | 12598065
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Azetidines
- Benzylamines
- Enoxaparin
- Fibrinolytic Agents
- Hirudins
- Recombinant Proteins
- ximelagatran
- Thrombin
|
Topics |
- Administration, Oral
- Adult
- Azetidines
(administration & dosage, pharmacology)
- Benzylamines
- Dose-Response Relationship, Drug
- Enoxaparin
(pharmacology)
- Fibrinolytic Agents
(pharmacology)
- Hirudins
(pharmacology)
- Humans
- Male
- Platelet Activation
(drug effects)
- Recombinant Proteins
(pharmacology)
- Reference Values
- Thrombin
(antagonists & inhibitors, biosynthesis, drug effects)
|